April 30, 2024 7:51am

The expression is used to describe the notion that share pricing will decide the outcome of a course of events, even if and as volatile action is taken to try to alter it

News: AxoGen (AXGN aftermarket $0.00) announced the first surgical implantations of its newest product, Avive+ Soft Tissue Matrix™; a resorbable, multi-layer, placenta-based allograft that provides temporary protection and tissue separation during the critical phase of healing for nerves. Avive+ is processed and distributed as a 361-tissue product in accordance with FDA Good Tissue Practices under 21 CFR part 1271 regulations.

Pre-open Indications: 1 Sell into Strength, 1 Positive and 2 Negative Indications

Earnings: MiMedx (MDXG)

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing money in your portfolio for the short and near-term

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.

 

Tuesday: The pre-open Dow futures are DOWN -0.05% or (-20 points), the S&P futures are DOWN -0.07% or (-3 points) as the Nasdaq futures are DOWN -0.13% or (-23 points)

Futures are flipping down, Tuesday, 4/30/24,

European markets were mixed,

Asia-Pacific markets largely rose.

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday: The Dow closed UP +146.43 points or +0.38%, the S&P closed UP +16.21 points or +0.32% while the Nasdaq closed UP +55.18 points or +0.35%.

Fed policymakers are convening for their two-day policy meeting …

Economic Data Docket: Conference Board Consumer Confidence, April (104.1 expected, 104.7 previously); Employment cost index, Q1 (+1% expected, +0.9% prior);

  • S&P CoreLogic Case-Shiller, 20-City Composite home price index, month-over-month, February (+0.1% expected, +0.14% previously); S&P CoreLogic Case-Shiller 20-City Composite home price index, year-over-year, February (+6.59% previously)
  • The Fed will release its latest interest rate announcement on Wednesday and April’s nonfarm payrolls report on Friday.

 

Monday night’s RegMed Investors (RMi) Closing Bell: “a month of up, downs; I thought were exercise. As April comes almost to the end, the cell and gene therapy sector plants its legs in a positive session.” … https://www.regmedinvestors.com/articles/13438

 

Q2/24:  April - 15 negative and 6 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Sell-into-Strength Indication:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Regenxbio (RGNX) closed up +$0.14 after Friday’s +$0.13, Thursday’s +$0.02, Wednesday’s +$0.14 and last Tuesday’s +$0.26 with a neutral pre-open indication.

 

Negative Indication:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

CRISPR Therapeutics (CRSP +$0.92 after Friday’s +$0.18, after Thursday’s -$1.92, Wednesday’s -$0.76, and last Tuesday’s +$0.75 and the previous Monday’s +$0.61 with a negative -$0.03 or -0.05% pre-open indication

Lenz Therapeutics (LENZ) closed up +$0.78, Friday’s +$0.27 and Thursday’s -$0.41 and Friday’s -$0.06 with a neutral pre-open indication

 

Positive Indication:

Monday, Friday, Thursday, Wednesday, Tuesday and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)

Alnylam Pharmaceuticals (ALNY) closed up +$4.05 after Friday’s -$0.40 with a neutral pre-open indication.

 

The BOTTOM LINE:  end of month coming on Wednesday … as earnings ramp-up.

  • Traders are this week reviewing more corporate earnings, key labor data and a Fed meeting foe what’s to come.

 

“The YTD<year-to-date> upgrade in the market’s pricing of economic growth largely explains the resilience in equities this year alongside the climb higher in interest rates. “However, during the past few weeks, the driver of rates has shifted from better growth to hawkish monetary policy concerns, which has been more difficult for stocks to digest.” <David Kostin, Goldman Sachs’ chief U.S. equity strategist>

 

“I hate to be negative or contrarian but, this is a NO spin zone and pricing truth is its product; I can always be WRONG but, I am mostly EARLY!”

If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct business school (MBA) professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and just about … everything.

Also, as a quantamental “plotter” I equate myself to a quantitative analyst straddling fundamental stock picking to produce better results for investors. the term “quantamental,” blends the two styles setting forth my difference retail, trading and multiple investor categories.

 

The cell and gene therapy sector is still in play as earning season comes with a full wind…

  • While on Friday, the cell and gene therapy sector erased gains closing positive on Friday, closing down on Thursday, Wednesday after positive closes on Tuesday and Monday.

Q1/24 Reporting Season:

  • Alnylam Pharmaceuticals (ALNY), Ultragenyx Pharmaceuticals (RARE), AxoGen (AXGN), Blueprint Medicine (BPMC) on Thursday, 5/2;
  • Ionis Pharmaceuticals (IONS) and Agenus (AGEN) on Tuesday, 5/7,
  • Vericel (VCEL) on Wednesday, 5/8

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.